Yan Junfang, Zheng Ziye, Zhu Jiawei, Hu Ke, Hou Xiaorong, Shen Jie, Lian Xin, Sun Shuai, Miao Zheng, Shen Jing, Guan Hui, Meng Qingyu, Zhang Fuquan
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Front Oncol. 2021 Sep 13;11:744871. doi: 10.3389/fonc.2021.744871. eCollection 2021.
The role of salvage radiotherapy (RT) in the treatment for vaginal recurrence of cervical cancer in patients after prior surgery remains controversial. The aim of this study was to evaluate the efficacy and toxicity of salvage RT and explore prognostic factors associated with the survival after recurrence.
Patients with cervical cancer, treated for vaginal recurrences at Peking Union Medical College Hospital between July 2011 and November 2019, were identified. All the patients underwent prior surgery for primary tumor and received salvage RT including external beam radiotherapy (EBRT), brachytherapy (BT), or both. The irradiation field and dose depended on the conditions of patients. Recurrence patterns were classified into four categories according to the site of recurrence. Prognostic factors on the overall survival (OS), progression-free survival (PFS), and local control (LC) were analyzed, and late toxicity was evaluated.
A total of 141 patients were included in the analysis, with a median follow-up time of 40.8 months. The estimated 5-year OS, PFS, and LC rates were 81%, 75%, and 87%, respectively. In multivariate analysis, endovaginal recurrence and no irradiation history were favorable prognostic factors associated with OS (all p < 0.05), PFS (all p < 0.05), and LC (all p < 0.05). The area under the receiver operating characteristic (ROC) curve (AUC) of the recurrence pattern is larger than the stage of primary tumor (0.734 . 0.670).
RT was an effective treatment with tolerable toxicity for vaginal recurrences of cervical cancer in patients with prior surgery. Recurrence pattern and irradiation history were important prognostic factors.
挽救性放疗(RT)在既往接受过手术的宫颈癌患者阴道复发治疗中的作用仍存在争议。本研究旨在评估挽救性放疗的疗效和毒性,并探讨复发后生存相关的预后因素。
确定2011年7月至2019年11月在北京协和医院接受阴道复发治疗的宫颈癌患者。所有患者均接受过原发性肿瘤的前期手术,并接受了挽救性放疗,包括外照射放疗(EBRT)、近距离放疗(BT)或两者联合。照射野和剂量取决于患者情况。根据复发部位将复发模式分为四类。分析总生存(OS)、无进展生存(PFS)和局部控制(LC)的预后因素,并评估晚期毒性。
共141例患者纳入分析,中位随访时间为40.8个月。估计的5年OS、PFS和LC率分别为81%、75%和87%。多因素分析中,阴道内复发和无放疗史是与OS(均p<0.05)、PFS(均p<0.05)和LC(均p<0.05)相关的有利预后因素。复发模式的受试者工作特征(ROC)曲线下面积(AUC)大于原发性肿瘤分期(0.734对0.670)。
对于既往接受过手术的宫颈癌患者阴道复发,放疗是一种毒性可耐受的有效治疗方法。复发模式和放疗史是重要的预后因素。